Fig. 3: Intranasal vaccination with RBD-fused MSA in female BALB/c mice induces robust antigen-specific antibodies beyond that of intramuscular vaccination. | Nature Communications

Fig. 3: Intranasal vaccination with RBD-fused MSA in female BALB/c mice induces robust antigen-specific antibodies beyond that of intramuscular vaccination.

From: An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models

Fig. 3

a Illustration of intranasal vaccination with an RBD-albumin fusion compared with intramuscular vaccination with the mRNA vaccine from BioNTech-Pfizer (Comirnaty/BNT162b2), and the vaccination regimen in female BALB/c mice. b RBD-specific IgG and IgA in sera and BALF at endpoint after vaccination of BALB/c mice (prime dose: 6.2 µg RBD and 19.9 µg RBD-MSA in combination with 20 μg CpG, 3 μg Comirnaty, or PBS), and c the ability of the antibodies to inhibit human ACE2-RBD binding. d Percentage of B-cells that are antigen-specific in mediastinal lymph nodes detected by flow cytometry. All serology detected using FCBA. Bars indicating group mean ± SD with individual mice represented as a single datapoint (b PBS and BnT-Pfizer n = 5, and RBD and RBD-MSA n = 6, or c n = 5, except RBD-MSA n = 6). d All mediastinal lymph nodes per group (PBS and BnT-Pfizer n = 5, and RBD and RBD-MSA n = 6) were merged and samples prepared in technical triplicates for flow cytometry. b One-way ANOVA with Tukey’s multiple comparison and c Kruskal–Wallis test with Dunn’s multiple comparison. a Created or b and c partially created in BioRender86.

Back to article page